PML and neoplasm: Patients with lower expression levels of promyelocytic leukemia (PML) or procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 (PLOD3) in tumor showed significantly higher ORR (Fig. 3d, f) and longer PFS (PML: 4.9 vs. 13.9 months, HR = 5.53, 95% CI 1.6–19.7; PLOD3: 4.4 vs. 10.3 months, HR = 4.78, 95% CI 1.8–12.6, Fig. 3e, g) compared with those with higher expression of PML or PLOD3 protein.